102 related articles for article (PubMed ID: 21417773)
1. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).
Malherbe P; Ballard TM; Ratni H
Expert Opin Ther Pat; 2011 May; 21(5):637-55. PubMed ID: 21417773
[TBL] [Abstract][Full Text] [Related]
2. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling of neurokinin B and tachykinin NK₃ receptor complex.
Ganjiwale AD; Rao GS; Cowsik SM
J Chem Inf Model; 2011 Nov; 51(11):2932-8. PubMed ID: 21913652
[TBL] [Abstract][Full Text] [Related]
4. Neurokinin receptor antagonism: a patent review (2014-present).
Muñoz M; Coveñas R
Expert Opin Ther Pat; 2020 Jul; 30(7):527-539. PubMed ID: 32401556
[TBL] [Abstract][Full Text] [Related]
5. Antagonists at the neurokinin receptors--recent patent literature.
Giardina GA; Gagliardi S; Martinelli M
IDrugs; 2003 Aug; 6(8):758-72. PubMed ID: 12917772
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
de la Flor R; Dawson LA
Neuropharmacology; 2009 Feb; 56(2):342-9. PubMed ID: 18822303
[TBL] [Abstract][Full Text] [Related]
7. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?
Spooren W; Riemer C; Meltzer H
Nat Rev Drug Discov; 2005 Dec; 4(12):967-75. PubMed ID: 16341062
[TBL] [Abstract][Full Text] [Related]
8. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.
Malherbe P; Bissantz C; Marcuz A; Kratzeisen C; Zenner MT; Wettstein JG; Ratni H; Riemer C; Spooren W
Mol Pharmacol; 2008 Jun; 73(6):1736-50. PubMed ID: 18308898
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of senktide-induced tail whips.
Nordquist RE; Ballard TM; Algeyer B; Pauly-Evers M; Ozmen L; Spooren W
Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition.
Tian G; Wilkins D; Scott CW
Mol Pharmacol; 2007 Mar; 71(3):902-11. PubMed ID: 17172464
[TBL] [Abstract][Full Text] [Related]
11. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?
Griebel G; Beeské S
Pharmacol Ther; 2012 Jan; 133(1):116-23. PubMed ID: 21963368
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
13. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
15. Bronchoconstrictor effect of the tachykinin NK₃-receptor agonists [MePhe⁷]-neurokinin B and senktide in the isolated guinea pig lung.
Corboz MR; Rivelli MA; Eckel SP
Exp Lung Res; 2010 Nov; 36(9):509-21. PubMed ID: 20939761
[TBL] [Abstract][Full Text] [Related]
16. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.
Nagano M; Saitow F; Haneda E; Konishi S; Hayashi M; Suzuki H
Br J Pharmacol; 2006 Feb; 147(3):316-23. PubMed ID: 16331282
[TBL] [Abstract][Full Text] [Related]
17. Tachykinin receptor subtypes in the isolated guinea pig heart and their role in mediating responses to neurokinin A.
Chang Y; Hoover DB; Hancock JC; Smith FM
J Pharmacol Exp Ther; 2000 Jul; 294(1):147-54. PubMed ID: 10871306
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of activation of peripheral and spinal tachykinin neurokinin(3) receptors on the micturition reflex in rats.
Kamo I; Chancellor MB; de Groat WC; Yoshimura N
J Urol; 2005 Aug; 174(2):776-81. PubMed ID: 16006975
[TBL] [Abstract][Full Text] [Related]
19. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
Dawson LA; Porter RA
Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945
[TBL] [Abstract][Full Text] [Related]
20. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.
Malherbe P; Kratzeisen C; Marcuz A; Zenner MT; Nettekoven MH; Ratni H; Wettstein JG; Bissantz C
J Med Chem; 2009 Nov; 52(22):7103-12. PubMed ID: 19817444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
